Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Acura Pharmaceuticals, Inc. (ACUR)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.48000.0000 (0.00%)
At close: 03:33PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4800
Open0.4500
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.4500 - 0.4800
52 Week Range0.1900 - 0.7500
Volume1,126
Avg. Volume9,590
Market Cap31.243M
Beta (5Y Monthly)0.63
PE Ratio (TTM)N/A
EPS (TTM)-0.0290
Earnings DateMar 29, 2022 - Apr 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Acura Pharmaceuticals Announces Third Quarter 2021 Financial Results

    PALATINE, Ill., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications, announced today financial results for the three and nine months ended September 30, 2021. The Company reported revenues of $270 thousand, an operating loss of $531 thousand and a net loss of $262 thousand or $0.00 per diluted share for th

  • GlobeNewswire

    Acura Pharmaceuticals Announces Second Quarter 2021 Financial Results

    PALATINE, Ill., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications, announced today financial results for the three and six months ended June 30, 2021. The Company reported revenues of $613 thousand and an operating loss of $300 thousand for the second quarter 2021 compared to revenues of $1.4 million and

  • GlobeNewswire

    Acura Pharmaceuticals and AD Pharma Amend License to LIMITx™ LTX-03

    Amendment Extends NDA Acceptance DatePALATINE, Ill., July 26, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced an amendment to its License, Development and Commercialization Agreement (“Agreement”) regarding Acura’s LIMITx™ LTX-03 product candidate with Abuse Deterrent Pharma, LLC (“AD Pharma”) to extend the FDA Acceptance Date for LTX-03 (“NDA Acceptance Date”) to February 28, 2022. LTX-03 (hydrocodone with acetaminophen)Recent reports suggest growing numbers o

Advertisement
Advertisement